Abstract YO8
Case summary
Carcinosarcoma of the breast is an aggressive, malignant biphasic neoplasm. It is comprised of carcinomatous and sarcomatous elements and accounts for 0.08–0.2% of all breast malignancies. Due to the rarity of this disease, it remains poorly understood and infrequently reported. Here we present a case of a 38 year old Filipino woman with a 2 month history of mass in her left breast. Progressive enlargement of the mass warranted excisional biopsy and revealed high grade carcinoma. Metastatic work up were unremarkable. Thus, the patient underwent modified radical mastectomy. Histopathology revealed metaplastic carcinoma, carcinosarcoma type with background of ductal carcinoma in-situ, nuclear grade 1 with no definite lymphovascular space invasion. All 12 lymph nodes were negative for tumor but nipple was positive for tumor. Immunohistochemistry report revealed positive for ER, PR and negative for HER2/Neu overexpression. Furthermore, tumor cells were positive for pancytokeratin in carcinomatous areas and vimentin in sarcomatous areas. The patient is receiving hormonal therapy and remains to be asymptomatic and on close surveillance.
A multi-disciplinary approach with an accurate diagnosis are essential to optimally tailor potentially effective treatment options in this kind of patients. To date, there is no standardized treatment protocol for the management of carcinosarcoma of the breast. Long-term follow-up is important because of the increased likelihood of local recurrence and metastasis.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract
528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster display session
Resources:
Abstract
530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis
Presenter: Carla Emille Barbon
Session: Poster display session
Resources:
Abstract
531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
Presenter: Byoung Chul Cho
Session: Poster display session
Resources:
Abstract
532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
Presenter: Daniel Shao Weng Tan
Session: Poster display session
Resources:
Abstract
533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
Presenter: Darren Lim
Session: Poster display session
Resources:
Abstract
534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)
Presenter: Kohei Otsubo
Session: Poster display session
Resources:
Abstract
535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)
Presenter: Satoshi Ikeda
Session: Poster display session
Resources:
Abstract
536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Presenter: James C-H Yang
Session: Poster display session
Resources:
Abstract
YO9 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone
Presenter: Gusti Harti
Session: Poster display session
Resources:
Abstract